Ignite Creation Date:
2024-05-06 @ 1:44 AM
Last Modification Date:
2024-10-26 @ 11:09 AM
Study NCT ID:
NCT01888575
Status:
COMPLETED
Last Update Posted:
2014-05-13
First Post:
2013-03-18
Brief Title:
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is conducted in a cohort of low dose aspirin ASA users previously ascertained The aims of the post hoc analyses are
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use crude and adjusted by confounding
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex
To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use crude and adjusted by confounding
To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex
To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy
Detailed Description:
Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None